Cargando…
Human Subject Protection In India – Is It Adequate?
India′s experience in clinical trials is shorter in time than that of the developed countries but as in everything else in the current globalizing environment, business compulsions characterized by compressed timelines are strong persuaders to catch up. Most global pharmaceutical and biotechnology o...
Autor principal: | Mahaluxmivala, Narges |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149402/ https://www.ncbi.nlm.nih.gov/pubmed/21829776 |
Ejemplares similares
-
Ethics committees in India: Facing the challenges!
por: Kadam, Rashmi, et al.
Publicado: (2012) -
2030: “Understandable to the subject”: Plain language IRB informed consents
por: Moore, Tina, et al.
Publicado: (2018) -
2530: Should all clinical research subjects pay the same?
por: McKinney, Bernadette
Publicado: (2018) -
Patient Protection in Clinical Trials in India: Some Concerns
por: Srinivasan, Sandhya
Publicado: (2010) -
A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa
por: Limaye, Dnyanesh, et al.
Publicado: (2015)